U
IDIX

UBS’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

UBS’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-35,300
Closed -$851K – 11313
2014
Q2 		$851K Buy
35,300
+30,100
+579% +$314K ﹤0.01% 3707
2014
Q1 		$31K Sell
5,200
-1,300
-20% -$9.07K ﹤0.01% 7517
2013
Q4 		$39K Buy
6,500
+4,100
+171% +$19K ﹤0.01% 7303
2013
Q3 		$12K Sell
2,400
-100
-4% -$438 ﹤0.01% 8684
2013
Q2 		$9K Buy
+2,500
New +$10.2K ﹤0.01% 8789

UBS's IDIX Position: Q3 2014 in Review

UBS sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2014, closing a stake of 80,677 shares — an estimated $1.94M sold.

UBS first reported a position in IDIX in Q2 2013 and held it in 5 quarters. The position peaked at $2.13M in Q2 2013. 0 funds tracked by Wall St. Rank hold IDIX as of Q3 2014.

  • UBS reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2014 after selling out during the quarter.
  • UBS sold 80,677 IDENIX PHARMACEUTICALS INC shares in Q3 2014, an estimated $1.94M.
  • UBS first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 5 quarters.
  • UBS's IDENIX PHARMACEUTICALS INC position peaked at $2.13M in Q2 2013.
  • 0 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.